Tarus Therapeutics is a clinical stage biotech developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with potential first-in-class and best-in-class programs. Its two lead programs have IND clearance and will be entering clinical trials in 2022.
Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Harbour Mice® platforms generate fully human mAbs (H2L2), as well as heavy chain only (HCAb) format. The HCAb-based immune cell engagers (HBICE®) delivers tumor killing effects unachievable by traditional therapies. The Company is building robust portfolio and differentiated pipeline through internal R&D, co-discovery and co-development partnership and select acquisitions.